{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:46:01Z","timestamp":1794296761106,"version":"4.9.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>PSMA PET\/CT is commonly used for selecting candidates for [\u00b9\u2077\u2077Lu]-PSMA radioligand therapy (LuPSMA RLT). However, discrepancies may occur due to pharmacokinetic and biodistribution differences between [\u2076\u2078Ga]-PSMA-11 and [\u00b9\u2077\u2077Lu]-PSMA-617 ligands. Such discordance risks underestimating disease burden and excluding eligible patients. We present a case of metastatic castration-resistant prostate cancer (mCRPC) in whom a PSMA-negative adrenal lesion on PET exhibited significant LuPSMA uptake post-therapy and was subsequently confirmed as FDG-avid. Complementary stereotactic body radiotherapy (SBRT) achieved metabolic remission. This case highlights the clinical significance of integrating post-therapy LuPSMA imaging and FDG PET\/CT with systemic treatment to ensure accurate disease characterization and personalized management of PSMA\u2212\/FDG+ lesions in advanced prostate cancer.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006293","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:00:11Z","timestamp":1767207611000},"page":"e659-e661","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Imaging Discordance Between [\u2076\u2078Ga]-PSMA PET and [\u00b9\u2077\u2077Lu]-PSMA SPECT in mCRPC"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6875-0666","authenticated-orcid":false,"given":"Cansu","family":"K\u00fc\u00e7\u00fcker","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Hacettepe University Faculty of Medicine, Ankara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrsan","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Republic of T\u00fcrkiye, Ministry of Health, Yozgat State Hospital, Yozgat, T\u00dcRK\u0130YE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eser Lay","family":"Erg\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hacettepe University Faculty of Medicine, Ankara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"U\u011fur","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hacettepe University Faculty of Medicine, Ankara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Tuncel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hacettepe University Faculty of Medicine, Ankara"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"12","key":"R1-20260702","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"R2-20260702","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT.","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13550-024-01190-7","article-title":"Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy","volume":"15","author":"Heilinger","year":"2025","journal-title":"EJNMMI Res"},{"key":"R5-20260702","first-page":"242346","article-title":"The use of advanced medical imaging to augment receptor-based radiopharmaceutical therapy","volume":"65(supplement 2)","author":"Fermawi","year":"2024","journal-title":"J Nucl Med"},{"key":"R6-20260702","first-page":"251407","article-title":"Clinical utility of post-therapy SPECT\/CT after the 1st cycle of 177Lu-PSMA-617 therapy in detecting interim disease progression compared to pre-therapy PSMA PET\/CT","volume":"66(supplement 1)","author":"singh Parihar","year":"2025","journal-title":"J Nucl Med"},{"key":"R7-20260702","article-title":"PSMA\/FDG discordance: 24-hour [177Lu]-PSMA-617 SPECT versus 60-minute [68Ga]-PSMA-11 PET.","author":"Mercier","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"R8-20260702","first-page":"1939","article-title":"Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT\/CT and Pretherapy PSMA PET\/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.","volume":"65","author":"Swiha","year":"2024","journal-title":"J Nucl Med"},{"issue":"5","key":"R9-20260702","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12149-021-01593-9","article-title":"Predictive factors of tumor sink effect: Insights from (177)Lu-Prostate-specific membrane antigen therapy.","volume":"35","author":"Tuncel","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.3390\/cancers13164134","article-title":"Value of combined PET Imaging with [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in mCRPC patients with worsening disease during [(177)Lu]Lu-PSMA-617 RLT","volume":"13","author":"Khreish","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"R11-20260702","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2967\/jnumed.121.263274","article-title":"The VISION Forward: Recognition and Implication of PSMA-\/(18)F-FDG+ mCRPC.","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"R12-20260702","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.euo.2022.02.002","article-title":"Stereotactic radiotherapy for lesions detected via (68)Ga-prostate-specific membrane antigen and (18)F-fluorodexyglucose positron emission tomography\/computed tomography in patients with nonmetastatic prostate cancer with early prostate-specific antigen progression on androgen deprivation therapy: a prospective single-center study","volume":"5","author":"Pan","year":"2022","journal-title":"Eur Urol Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:55:17Z","timestamp":1786035317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006293","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"2025-09-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}